PE20141672A1 - FORMULACION PARA ANTICUERPO ANTI-alfa4�7 - Google Patents

FORMULACION PARA ANTICUERPO ANTI-alfa4�7

Info

Publication number
PE20141672A1
PE20141672A1 PE2013002433A PE2013002433A PE20141672A1 PE 20141672 A1 PE20141672 A1 PE 20141672A1 PE 2013002433 A PE2013002433 A PE 2013002433A PE 2013002433 A PE2013002433 A PE 2013002433A PE 20141672 A1 PE20141672 A1 PE 20141672A1
Authority
PE
Peru
Prior art keywords
alpha4
antibody
formulation
chelant
antioxidant
Prior art date
Application number
PE2013002433A
Other languages
English (en)
Inventor
Willow Diluzio
Phuong M Nguyen
Csanad M Varga
Vaithianathan Palaniappan
Jason Brown
Irving H Fox
Catherine Scholz
Helen Jenkins
Maria Rosario
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147702&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141672(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20141672A1 publication Critical patent/PE20141672A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA LIQUIDA ESTABLE QUE COMPRENDE: A) UN ANTICUERPO ANTI-alfa4�7, EL CUAL TIENE UNA ESPECIFICIDAD DE UNION POR LA INTEGRINA alfa4�7 HUMANA; B) UN ANTIOXIDANTE O QUELANTE; C) UN AMINOACIDO LIBRE TAL COMO HISTIDINA, ALANINA, ARGININA, ENTRE OTROS; ADEMAS PUEDE CONTENER UN TENSIOACTIVO. LA PROPORCION MOLAR DEL ANTICUERPO ANTI-alfa4�7 RESPECTO AL ANTIOXIDANTE O QUELANTE ES DE 1:4 A 1:100; Y LA PROPORCION MOLAR DEL ANTIOXIDANTE O QUELANTE RESPECTO AL TENSIOACTIVO ES DE 3:1 A 156:1 DICHA FORMULACION ES UTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD INFLAMATORIA DEL INTESTINO
PE2013002433A 2011-05-02 2012-05-02 FORMULACION PARA ANTICUERPO ANTI-alfa4�7 PE20141672A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481522P 2011-05-02 2011-05-02
US201161544054P 2011-10-06 2011-10-06

Publications (1)

Publication Number Publication Date
PE20141672A1 true PE20141672A1 (es) 2014-11-26

Family

ID=46147702

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002433A PE20141672A1 (es) 2011-05-02 2012-05-02 FORMULACION PARA ANTICUERPO ANTI-alfa4�7

Country Status (37)

Country Link
US (6) US10040855B2 (es)
EP (2) EP3311834A1 (es)
JP (5) JP6190359B2 (es)
KR (7) KR102308938B1 (es)
CN (4) CN108969761A (es)
AR (1) AR086238A1 (es)
AU (5) AU2012250872B2 (es)
CA (2) CA3051418C (es)
CL (3) CL2013003145A1 (es)
CO (1) CO6801648A2 (es)
CR (1) CR20130556A (es)
CY (1) CY1119436T1 (es)
DK (1) DK2704742T3 (es)
DO (1) DOP2013000252A (es)
EA (1) EA032625B1 (es)
EC (1) ECSP22046340A (es)
ES (1) ES2646717T3 (es)
GE (1) GEP20186866B (es)
HK (1) HK1253911A1 (es)
HR (1) HRP20171457T1 (es)
HU (1) HUE036664T2 (es)
IL (6) IL305583A (es)
LT (1) LT2704742T (es)
ME (1) ME02858B (es)
MX (4) MX367097B (es)
MY (1) MY188820A (es)
PE (1) PE20141672A1 (es)
PH (2) PH12018502221A1 (es)
PL (1) PL2704742T3 (es)
PT (1) PT2704742T (es)
RS (1) RS56429B1 (es)
SG (1) SG194730A1 (es)
SI (1) SI2704742T1 (es)
TW (4) TWI799757B (es)
UY (1) UY34054A (es)
WO (1) WO2012151247A2 (es)
ZA (2) ZA201308168B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
NZ609557A (en) * 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
CN103635489B (zh) 2011-01-06 2016-04-13 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
CN103782172A (zh) 2011-07-06 2014-05-07 雀巢产品技术援助有限公司 检测针对使用TNFα的生物疗法的中和性自体抗体的测定法
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9764093B2 (en) * 2012-11-30 2017-09-19 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
CN105051068A (zh) 2013-03-15 2015-11-11 戴埃克斯有限公司 抗血浆激肽释放酶抗体
JP6908998B2 (ja) * 2013-07-05 2021-07-28 ステラー・バイオウム・インコーポレーテッド 口腔組成物
US9700595B2 (en) * 2013-11-29 2017-07-11 Ares Trading Sa Liquid formulation of a fusion protein comprising TNFR and Fc region
WO2016057424A1 (en) 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
RU2748841C2 (ru) * 2014-12-03 2021-05-31 Цсл Беринг Аг Фармацевтический продукт с увеличенной стабильностью, содержащий иммуноглобулины
CA2969609C (en) 2014-12-05 2023-02-28 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
WO2016160926A1 (en) * 2015-03-30 2016-10-06 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
EA201891388A1 (ru) 2015-12-11 2018-11-30 Дайэкс Корп. Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
EP3397287A1 (en) * 2015-12-30 2018-11-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
AU2017234009A1 (en) 2016-03-14 2018-09-27 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
BR112018068625A2 (pt) 2016-03-14 2019-07-30 Millennium Pharm Inc métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
EP3452070A1 (en) 2016-05-04 2019-03-13 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating inflammatory bowel disease
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
PE20191436A1 (es) * 2016-12-23 2019-10-14 Serum Institute Of India Pvt Ltd Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
CN108686204A (zh) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 包含组氨酸缓冲体系的英夫利西单抗组合物
BR112019022268A2 (pt) * 2017-04-28 2020-05-19 Millennium Pharm Inc método para o tratamento de distúrbios pediátricos
CN111278863A (zh) * 2017-08-25 2020-06-12 奥默罗斯公司 高浓缩低粘度masp-2抑制性抗体制剂、试剂盒和治疗患有非典型溶血综合征的受试者的方法
US20210147555A1 (en) * 2018-04-10 2021-05-20 Dr. Reddy?s Laboratories Limited Antibody formulation
AU2019251453A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy’S Laboratories Limited Stable formulations of therapeutic antibody
BR112020020741A2 (pt) * 2018-04-10 2021-01-19 Dr. Reddy's Laboratories Limited Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável.
US20210187107A1 (en) * 2018-08-29 2021-06-24 Glaxosmithkline Intellectual Property Development Limited Methods of preparing stable liquid therapeutic protein compositions
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
US20220259291A1 (en) * 2019-06-10 2022-08-18 Takeda Pharmaceutical Company Limited Antibody purification methods and compositions thereof
CN114746439A (zh) * 2019-10-11 2022-07-12 雷迪博士实验室有限公司 整合蛋白抗体的稳定制剂
IL300133A (en) * 2020-07-31 2023-03-01 Genentech Inc Anti-integrin antibody compositions in cell 7 and devices
US20240101679A1 (en) * 2020-12-09 2024-03-28 Dr. Reddy’S Laboratories Limited Stable aqueous buffer free formulation of an integrin antibody
WO2022253994A1 (en) * 2021-06-04 2022-12-08 Polpharma Biologics S.A. Vedolizumab formulation
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
WO2023126411A1 (en) 2021-12-27 2023-07-06 Polpharma Biologics S.A. Vedolizumab formulation
WO2023230620A1 (en) * 2022-05-27 2023-11-30 Sonnet BioTherapeutics, Inc. Il-12-albumin-binding domain fusion protein formulations and methods of use thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
ATE114478T1 (de) 1987-08-11 1994-12-15 Univ Leland Stanford Junior Verfahren zur kontrolle der leukozyten- extravasation.
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
EP0462111A4 (en) 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3854306B2 (ja) 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
DK0625912T3 (da) 1992-02-12 1997-10-27 Biogen Inc Behandling af inflammatorisk tarmsygdom
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU4390893A (en) 1992-05-21 1993-12-13 Center For Blood Research, Inc., The A novel receptor for alpha4 integrins and methods based thereon
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
NZ262615A (en) 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
CN1211123C (zh) 1994-01-25 2005-07-20 雅典娜神经科学公司 抗白细胞粘附分子vla－4的人源化抗体
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
MX9706049A (es) 1995-02-10 1998-02-28 Leukosite Inc Adresinas vasculares mucosas y sus usos.
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
PT2336184E (pt) 2002-02-25 2015-03-09 Biogen Idec Inc Administração de agentes para o tratamento da inflamação
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CN101077867B (zh) 2002-11-18 2012-10-10 坎莫森特里克斯公司 芳基磺酰胺
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
WO2004075913A1 (ja) 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha タンパク質含有安定化製剤
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
RS57636B1 (sr) 2004-09-03 2018-11-30 Genentech Inc Humanizovani anti-beta7 antagonisti i njihova upotreba
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2600836A1 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
WO2009074634A2 (en) * 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
MEP39508A (en) 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
US9111016B2 (en) 2007-07-06 2015-08-18 Stereotaxis, Inc. Management of live remote medical display
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
CN101533504A (zh) * 2009-04-27 2009-09-16 刘文祥 电子医务***及其装置
MX2012009755A (es) 2010-02-26 2012-09-12 Novo Nordisk As Composiciones que contienen anticuerpo estable.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.

Also Published As

Publication number Publication date
EP2704742A2 (en) 2014-03-12
IL305583A (en) 2023-10-01
ME02858B (me) 2018-04-20
AU2019216679A1 (en) 2019-09-05
KR102136208B1 (ko) 2020-07-21
TWI723339B (zh) 2021-04-01
PH12019501662A1 (en) 2021-03-15
CN103533959B (zh) 2018-06-05
JP2017137353A (ja) 2017-08-10
AR086238A1 (es) 2013-11-27
CR20130556A (es) 2014-03-05
MX2019009244A (es) 2019-09-13
JP2019052191A (ja) 2019-04-04
JP2022132430A (ja) 2022-09-08
SG194730A1 (en) 2013-12-30
TW201940195A (zh) 2019-10-16
AU2023274233A1 (en) 2023-12-21
AU2019216679B2 (en) 2021-09-23
WO2012151247A2 (en) 2012-11-08
LT2704742T (lt) 2017-10-25
AU2021225160A1 (en) 2021-09-30
PH12018502221A1 (en) 2019-10-28
DK2704742T3 (en) 2017-10-23
SI2704742T1 (sl) 2017-12-29
CY1119436T1 (el) 2018-03-07
NZ617340A (en) 2015-12-24
DOP2013000252A (es) 2013-12-31
KR102493433B1 (ko) 2023-01-27
CA3051418A1 (en) 2012-11-08
KR20230021758A (ko) 2023-02-14
HUE036664T2 (hu) 2018-07-30
CN107998388A (zh) 2018-05-08
IL272237A (en) 2020-02-27
BR112013028169A2 (pt) 2017-06-27
KR20170056713A (ko) 2017-05-23
TWI698254B (zh) 2020-07-11
ES2646717T3 (es) 2017-12-15
MX2013012725A (es) 2013-12-06
MX367097B (es) 2019-08-05
ZA201707310B (en) 2022-04-28
KR20190100451A (ko) 2019-08-28
RS56429B1 (sr) 2018-01-31
AU2012250872A1 (en) 2013-11-21
EA201391613A1 (ru) 2014-07-30
CA2834900C (en) 2021-03-02
MX354101B (es) 2018-02-13
JP2020180163A (ja) 2020-11-05
EP2704742B1 (en) 2017-07-12
CL2017000829A1 (es) 2017-12-29
AU2021225160B2 (en) 2023-12-21
WO2012151247A3 (en) 2013-02-28
KR101875155B1 (ko) 2018-07-09
US11560434B2 (en) 2023-01-24
US20180327497A1 (en) 2018-11-15
TW201813665A (zh) 2018-04-16
UY34054A (es) 2012-11-30
TWI638661B (zh) 2018-10-21
US10040855B2 (en) 2018-08-07
ECSP22046340A (es) 2022-07-29
CN108969469A (zh) 2018-12-11
CN107998388B (zh) 2023-07-14
KR20200088517A (ko) 2020-07-22
PL2704742T3 (pl) 2018-01-31
CN103533959A (zh) 2014-01-22
KR101884406B1 (ko) 2018-08-02
US20180346578A1 (en) 2018-12-06
KR20210120144A (ko) 2021-10-06
MY188820A (en) 2022-01-05
JP6751450B2 (ja) 2020-09-02
AU2017204192A1 (en) 2017-07-13
EA201391613A8 (ru) 2016-05-31
US20200377601A1 (en) 2020-12-03
IL290848A (en) 2022-04-01
KR102014512B1 (ko) 2019-08-26
KR20180080354A (ko) 2018-07-11
CA3051418C (en) 2021-05-18
TW201300128A (zh) 2013-01-01
MX2021008112A (es) 2022-06-02
IL290849A (en) 2022-04-01
AU2012250872B2 (en) 2017-07-13
US20230312727A1 (en) 2023-10-05
KR102493433B9 (ko) 2023-09-01
GEP20186866B (en) 2018-06-25
IL229169A0 (en) 2013-12-31
TW202133878A (zh) 2021-09-16
PT2704742T (pt) 2017-11-15
JP7107997B2 (ja) 2022-07-27
HRP20171457T1 (hr) 2017-11-03
EP3311834A1 (en) 2018-04-25
EA032625B1 (ru) 2019-06-28
IL274846A (en) 2020-07-30
IL272237B (en) 2022-05-01
US20140341885A1 (en) 2014-11-20
TWI799757B (zh) 2023-04-21
AU2017204192B2 (en) 2019-09-12
HK1253911A1 (zh) 2019-07-05
CL2020001579A1 (es) 2020-11-06
JP2014515763A (ja) 2014-07-03
TW202317193A (zh) 2023-05-01
JP6190359B2 (ja) 2017-08-30
KR102308938B1 (ko) 2021-10-01
IL229169B (en) 2020-06-30
CN108969761A (zh) 2018-12-11
ZA201308168B (en) 2018-11-28
CA2834900A1 (en) 2012-11-08
JP6467457B2 (ja) 2019-02-13
KR20140145952A (ko) 2014-12-24
US20210340261A1 (en) 2021-11-04
CL2013003145A1 (es) 2014-07-25
CO6801648A2 (es) 2013-11-29

Similar Documents

Publication Publication Date Title
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
PE20150200A1 (es) Formulacion de anticuerpos
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
NI201400083A (es) Compuesto de imidazopirrolidinona
BR112012017488A2 (pt) "dispositivo"
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
PE20142167A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
TR201908003T4 (tr) TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
MX344473B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
AR082422A1 (es) Composicion detergente liquida
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
EA201500245A1 (ru) Твердый фармацевтический препарат, который содержит левотироксин
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
BR112013028607A2 (pt) composições sólidas contendo éter glicólico e água
EA201391643A1 (ru) Составы с замедленным высвобождением парацетамола
BR112013019924A8 (pt) Composições para cuidado oral
MX2015016490A (es) Esteres sulfatados de acidos oligohidroxicarboxilicos, y uso de los mismos.

Legal Events

Date Code Title Description
FG Grant, registration